Identification of a Biomarker Signature to Predict the Need for Chemotherapy in Patients With Hormone Receptor Positive Breast Cancer

被引：0
|
作者：
Korf, U. [1 ]
Sonntag, J. [1 ]
Bender, C. [1 ]
Wiemann, S. [1 ]
Aulmann, S. [2 ]
Sinn, P. [2 ]
Burwinkel, B. [2 ]
Schneeweiss, A. [3 ]
Beissbarth, T. [4 ]
机构：
[1] German Canc Res Ctr, Heidelberg, Germany
[2] Univ Clin Heidelberg, Heidelberg, Germany
[3] Natl Ctr Tumor Dis Heidelberg, Gynecol Oncol Sect, Heidelberg, Germany
[4] Univ Med Ctr Gottingen, Gottingen, Germany
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
10.1016/S0959-8049(12)71480-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
847
引用
收藏
页码：S203 / S204
页数：2
相关论文
共 50 条
  • [1] Tidal chemotherapy in premenopausal patients with hormone receptor positive breast cancer
    Luo, Qing-qing
    Huang, Jian-bo
    Wu, Yu-tuan
    Li, Xin
    Zhao, Chun-xia
    Wu, He
    Dai, Wei
    Wu, Kai-nan
    Kong, Ling-quan
    MEDICAL HYPOTHESES, 2017, 102 : 4 - 7
  • [2] Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx® for Hormone Receptor Positive Patients Undergoing Neoadjuvant Chemotherapy
    Olga Kantor
    Ermilo Barrera
    Katherine Kopkash
    Catherine Pesce
    Ermilo Barrera
    David J. Winchester
    Katharine Yao
    Annals of Surgical Oncology, 2019, 26 : 3232 - 3239
  • [3] Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx® for Hormone Receptor Positive Patients Undergoing Neoadjuvant Chemotherapy
    Kantor, Olga
    Barrera, Ermilo
    Kopkash, Katherine
    Pesce, Catherine
    Barrera, Ermilo
    Winchester, David J.
    Yao, Katharine
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (10) : 3232 - 3239
  • [4] Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response
    Xing, Ai-Yan
    Wang, Bin
    Li, Yu-Hong
    Chen, Xu
    Wang, Ya-Wen
    Liu, Hai-Ting
    Gao, Peng
    PATHOLOGY & ONCOLOGY RESEARCH, 2021, 27
  • [5] The role of chemotherapy in hormone receptor positive advanced breast cancer
    Barrios Carlos, H.
    GACETA MEXICANA DE ONCOLOGIA, 2010, 9 (05): : 215 - 221
  • [6] TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast Cancer
    Jeselsohn, Rinath
    Barry, William T.
    Migliaccio, Ilenia
    Biagioni, Chiara
    Zhao, Jin
    De Tribolet-Hardy, Jonas
    Guarducci, Cristina
    Bonechi, Martina
    Laing, Naomi
    Winer, Eric P.
    Brown, Myles
    Di Leo, Angelo
    Malorni, Luca
    CLINICAL CANCER RESEARCH, 2016, 22 (23) : 5755 - 5764
  • [7] CEBPD (C/EBPδ) acts as a tumor suppressor in hormone receptor positive breast cancer cells and may serve as biomarker to predict the need for adjuvant therapy
    Mendoza-Villanueva, Daniel Y.
    Kim, Suryun
    Ali, H. Raza
    Sharan, Shikha
    Sarkar, Tapasree R.
    Caldas, Carlos
    Landberg, Goeran
    Sterneck, Esta
    CANCER RESEARCH, 2013, 73 (08)
  • [8] Prognostic Value of a Positive-to-negative Change in Hormone Receptor Status after Neoadjuvant Chemotherapy in Patients with Hormone Receptor–positive Breast Cancer
    Sheng Chen
    Can-Ming Chen
    Ke-Da Yu
    Ruo-Ji Zhou
    Zhi-Ming Shao
    Annals of Surgical Oncology, 2012, 19 : 3002 - 3011
  • [9] Impact of neoadjuvant chemotherapy on surgical outcomes among patients with hormone receptor positive breast cancer
    Hage, Andrew N.
    Capriccioso, Christina
    Brennan, Julia
    Heiden, Brendan
    Zheutlin, Alexander
    Sabel, Michael S.
    JOURNAL OF SURGICAL ONCOLOGY, 2017, 116 (06) : 665 - 670
  • [10] Influence of histology on the effectiveness of adjuvant chemotherapy in patients with hormone receptor positive invasive breast cancer
    Truin, Wilfred
    Voogd, Adri C.
    Vreugdenhil, Gerard
    van der Sangen, Maurice J. C.
    van Beek, Mike W. P. M.
    Roumen, Rudi M. H.
    BREAST, 2011, 20 (06): : 505 - 509
12345